Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
AlphaVax Inc
Citranvi Biosciences LLC
Helocyte Biosciences Inc
Merck & Co Inc
Stadius Biopharma LLC
Trellis Bioscience Inc
VBI Vaccines Inc
Yaso Therapeutics Inc
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
AVX-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bi-specific Monoclol Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytomegalovirus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit gH and gB for Cytomegalovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
Featured News & Press Releases
Jun 08, 2021: VBI Vaccines granted FDA fast track desigtion for VBI-1901 for the treatment of recurrent GBM
May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
Nov 19, 2020: VBI Vaccines announces positive interim Phase 2a data from VBI-1901 in recurrent GBM
Nov 09, 2020: VBI Vaccines announces e-poster presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
Sep 17, 2020: VBI Vaccines announces biomarker data from VBI-1901 phase 1/2a study in recurrent GBM presented at ESMO Virtual Congress 2020
Sep 14, 2020: VBI Vaccines to present additiol biomarker data from VBI-1901 phase 1/2a study in recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
Jun 22, 2020: VBI Vaccines announces data from VBI-1901 presented at AACR 2020: Partial response observed, promising biomarker strategy identified
May 15, 2020: VBI Vaccines announces upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
Mar 03, 2020: VBI Vaccines doses first recurrent GBM patient in trial of VBI-1901
Mar 03, 2020: VBI Vaccines provides update on part A of ongoing Phase 1/2a study demonstrating overall survival benefit for VBI-1901 vaccine responders in recurrent GBM patients
Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting
Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019
Sep 11, 2019: VBI to study cancer vaccine with GSK’s adjuvant system
Jul 29, 2019: VBI Vaccines announces dosing of first recurrent GBM patient in Part B of ongoing phase 1/2a study of VBI-1901
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AlphaVax Inc, 2021
Pipeline by Citranvi Biosciences LLC, 2021
Pipeline by Helocyte Biosciences Inc, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Stadius Biopharma LLC, 2021
Pipeline by Trellis Bioscience Inc, 2021
Pipeline by VBI Vaccines Inc, 2021
Pipeline by Yaso Therapeutics Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021